tatdn1 Antibody

What is TATDN1 and why is it significant in molecular biology research?

TATDN1 (TatD DNase domain containing 1) is a gene that encodes a protein involved in several critical cellular processes, including DNA repair, replication, and maintenance of genomic stability. The protein functions as a deoxyribonuclease that catalyzes the decatenation of kinetoplast DNA, converting circular DNA catenations into linear DNA molecules. TATDN1 plays an important role in chromosomal segregation and cell cycle progression, particularly during eye development, through its DNA decatenation activity .

The significance of TATDN1 in research has grown as studies have demonstrated its dysregulation in various pathological conditions, particularly cancer. Both the protein-coding gene and its function as a long non-coding RNA (lncRNA) have been implicated in disease processes, making it a valuable target for researchers investigating fundamental cellular mechanisms and disease pathogenesis .

What are the primary characteristics of commercially available TATDN1 antibodies?

Most commercial TATDN1 antibodies are polyclonal antibodies raised in rabbits. These antibodies typically recognize epitopes within human TATDN1 protein, with some designed to target specific regions such as amino acids 1-200 or 1-297 of the human TATDN1 protein (NP_114415.1) .

The characteristics of a representative TATDN1 polyclonal antibody include:

Researchers should evaluate the specific epitope recognition and validated applications when selecting a TATDN1 antibody for their experimental needs .

What experimental techniques have been validated for TATDN1 antibodies?

TATDN1 antibodies have been validated for several experimental applications, with Western blotting being the most commonly verified technique. Based on available literature and commercial data, the following applications have established protocols:

• Western Blot (WB): Primary application with recommended dilutions typically ranging from 1:500 to 1:2000. This technique allows for detection and semi-quantitative analysis of TATDN1 protein expression in cell and tissue lysates .

• Immunocytochemistry/Immunofluorescence (ICC/IF): Some TATDN1 antibodies have been validated for cellular localization studies, enabling visualization of TATDN1 subcellular distribution (primarily nuclear) .

• ELISA: Certain TATDN1 antibodies have been validated for enzyme-linked immunosorbent assay applications, allowing for quantitative measurement of TATDN1 in solution .

While these applications have established protocols, researchers should always perform preliminary validation in their specific experimental systems, as antibody performance can vary across different cell types and conditions.

How should researchers optimize Western blot protocols for TATDN1 detection?

Optimizing Western blot protocols for TATDN1 detection requires attention to several critical parameters:

• Sample Preparation:

  • TATDN1 is primarily localized in the nucleus; therefore, ensure complete nuclear protein extraction

  • Use fresh samples when possible and include protease inhibitors in lysis buffers

  • Positive control samples: LO2, A-549, or A-431 cell lysates have been verified to express detectable levels of TATDN1

• SDS-PAGE Conditions:

  • Use 10-12% polyacrylamide gels for optimal resolution of TATDN1 (~35-40 kDa)

  • Load 20-40 μg of total protein per lane for cell line samples

• Antibody Incubation:

  • Primary antibody: Start with 1:1000 dilution in 5% BSA or milk in TBST

  • Incubate overnight at 4°C for optimal signal-to-noise ratio

  • Secondary antibody: Anti-rabbit HRP-conjugated at 1:5000-1:10000 dilution

• Detection and Troubleshooting:

  • Use enhanced chemiluminescence (ECL) detection systems

  • For weak signals, consider extending primary antibody incubation time or increasing antibody concentration

  • For high background, increase washing steps and duration, or reduce antibody concentration

Researchers should note that optimization may be required for different cell types or experimental conditions, particularly when studying TATDN1 in the context of cancer cells where expression levels can vary significantly .

How does TATDN1 contribute to cisplatin resistance in non-small cell lung cancer?

Research has elucidated a novel regulatory pathway through which TATDN1 contributes to cisplatin (DDP) resistance in non-small cell lung cancer (NSCLC). TATDN1 functions as a long non-coding RNA that enhances DDP tolerance through a specific molecular mechanism:

TATDN1 acts as a competing endogenous RNA (ceRNA) that sponges miR-451, preventing it from suppressing its target TRIM66. This TATDN1/miR-451/TRIM66 regulatory axis has been demonstrated through multiple experimental approaches:

• Expression correlation: TATDN1 and TRIM66 are significantly upregulated while miR-451 is downregulated in NSCLC tissues and cell lines, with even higher expression disparities in DDP-resistant tumors and cells .

• Functional validation: Knockdown of TATDN1 improves DDP sensitivity in NSCLC cells both in vitro and in vivo, confirming its role in chemoresistance .

• Mechanism verification: Dual-luciferase reporter assays have demonstrated that TATDN1 directly interacts with miR-451, functioning as a molecular sponge. This interaction prevents miR-451 from suppressing TRIM66 expression, thereby contributing to DDP resistance .

• Clinical correlation: Survival analysis of 88 NSCLC patients who underwent cisplatin treatment revealed that patients with low TATDN1 expression showed improved survival rates following DDP chemotherapy, providing clinical evidence for its role in chemoresistance .

This regulatory pathway represents a potential therapeutic target for overcoming cisplatin resistance in NSCLC patients .

What mechanisms underlie TATDN1's involvement in cancer cell invasion and metastasis?

TATDN1 plays a significant role in promoting cancer cell invasion and metastasis through multiple molecular mechanisms. Studies using 95D and 95C NSCLC cell lines (with high and low metastatic potential, respectively) have revealed several pathways through which TATDN1 enhances invasive capabilities:

• Regulation of adhesion and motility proteins: TATDN1 knockdown experiments have demonstrated that TATDN1 modulates the expression of key proteins involved in cell adhesion and migration:

  • Suppressed expression of E-cadherin, an important mediator of cell-cell adhesion

  • Decreased expression of β-catenin and Ezrin, proteins crucial for cytoskeletal organization and cell motility

  • Affected HER2 expression, which initiates signaling pathways leading to cell proliferation and tumorigenesis

• Morphological and structural changes: Scanning electron microscope analysis revealed that TATDN1 knockdown caused:

  • Shrinking cell morphology

  • Shorter and thinner filopodia

  • Decreased microvillius formation

  • Smoother cell surface projections

• Functional impact on cellular processes: TATDN1 inhibition significantly reduced:

  • Cell proliferation (measured by MTT assay)

  • Cell adhesion (measured by Matrigel assay)

  • Cell invasion (measured by Matrigel invasion assay)

  • Cell migration (measured by transwell assay)

• In vivo validation: TATDN1 knockdown in a mouse model demonstrated inhibited tumor growth and metastasis, confirming its role in cancer progression. Immunohistochemical analysis showed lower expression of β-catenin and Ezrin in tumors from TATDN1-knockdown cells .

These findings collectively demonstrate that TATDN1 enhances the invasive and metastatic potential of cancer cells by modulating multiple proteins involved in cell adhesion, motility, and proliferation .

How can researchers distinguish between protein-coding and lncRNA functions of TATDN1?

Distinguishing between the protein-coding and lncRNA functions of TATDN1 requires a multi-faceted experimental approach:

• Expression analysis with subcellular fractionation:

  • Separate nuclear and cytoplasmic fractions

  • Perform RT-qPCR to detect TATDN1 RNA in both fractions

  • Higher nuclear localization often suggests lncRNA function, while cytoplasmic detection may indicate protein-coding potential

  • Use appropriate controls: GAPDH mRNA (cytoplasmic) and U6 snRNA (nuclear)

• Protein vs. RNA interference approaches:

  • For protein function: Use antibody-based techniques (Western blot, immunoprecipitation) to detect and manipulate TATDN1 protein

  • For lncRNA function: Use RNA interference (siRNA, shRNA) targeting TATDN1 transcript, followed by functional assays without necessarily affecting protein levels

  • Compare phenotypes between protein depletion and RNA interference to differentiate functions

• Differential inhibition strategies:

  • Use translation inhibitors (cycloheximide) to block protein synthesis while maintaining RNA function

  • Design frameshift mutations that disrupt the protein-coding sequence without affecting RNA structure

  • Compare phenotypic outcomes of these interventions

• Context-specific analysis:

  • In NSCLC research, TATDN1 has shown significant lncRNA functions related to cisplatin resistance and metastasis

  • For DNA repair research, focus on the protein's DNase function and interaction with DNA substrates

This integrated approach helps researchers appropriately attribute observed phenotypes to either the protein-coding or lncRNA functions of TATDN1, which is essential for accurate experimental design and interpretation .

What are the key technical considerations when validating a new TATDN1 antibody?

Validating a new TATDN1 antibody requires rigorous testing across multiple parameters to ensure specificity, sensitivity, and reproducibility:

• Specificity validation:

  • Knockout/knockdown controls: Compare signals between wild-type cells and those with TATDN1 knockdown (siRNA or shRNA) or knockout (CRISPR-Cas9)

  • Peptide competition assay: Pre-incubate antibody with immunizing peptide to confirm signal suppression

  • Multiple antibody comparison: Test multiple antibodies targeting different epitopes of TATDN1

  • Cross-reactivity assessment: Test against related proteins with similar domains

• Application-specific validation:

  • Western blot: Confirm single band at expected molecular weight (~35-40 kDa)

  • Immunocytochemistry: Verify nuclear localization pattern consistent with known TATDN1 distribution

  • ELISA: Establish standard curves with recombinant TATDN1 protein

• Signal optimization:

  • Titration experiments: Test multiple antibody concentrations (e.g., 1:500, 1:1000, 1:2000) to determine optimal signal-to-noise ratio

  • Incubation conditions: Compare overnight 4°C vs. room temperature incubations

  • Detection methods: Compare chemiluminescence vs. fluorescence-based detection

• Reproducibility assessment:

  • Test across multiple cell lines with known TATDN1 expression (e.g., LO2, A-549, A-431)

  • Perform technical and biological replicates

  • Document lot-to-lot variation if using multiple antibody batches

A systematic validation approach ensures reliable results and prevents misinterpretation of data when using TATDN1 antibodies for critical research applications .

How should researchers interpret contradictory data regarding TATDN1 expression in different cancer studies?

When confronted with contradictory data on TATDN1 expression across different cancer studies, researchers should consider several factors that may explain these discrepancies:

• Dual nature of TATDN1:

  • TATDN1 functions as both a protein-coding gene and a long non-coding RNA

  • Studies may be measuring different aspects (protein vs. RNA levels) without clear distinction

  • Clarify whether contradictory studies are examining the same molecular entity

• Methodological differences:

  • Antibody specificity: Different antibodies may recognize distinct epitopes or isoforms

  • RNA detection methods: qRT-PCR primers targeting different regions might detect specific transcript variants

  • Analysis techniques: Western blot vs. immunohistochemistry vs. RNA-seq can yield different results

• Biological context variations:

  • Cancer heterogeneity: Different subtypes within the same cancer classification may show varying TATDN1 expression

  • Disease stage: Expression may change during progression from early to advanced stages

  • Treatment status: Studies in the context of cisplatin suggest TATDN1 is upregulated in drug-resistant cells

• Functional context:

  • In NSCLC, TATDN1 shows higher expression in cells with higher metastatic potential (95D vs. 95C)

  • The functional impact (promoting invasion and metastasis) appears consistent even when absolute expression levels differ

• Experimental validation approach:

  • When encountering contradictory literature, validate expression in your specific experimental system

  • Use multiple detection methods (protein and RNA levels)

  • Include appropriate controls and reference cell lines (e.g., LO2, A-549, A-431)

By systematically evaluating these factors, researchers can better interpret seemingly contradictory data and design experiments that account for contextual variations in TATDN1 expression .

What are common technical challenges when working with TATDN1 antibodies and how can they be addressed?

Researchers working with TATDN1 antibodies may encounter several technical challenges. Here are common issues and their solutions:

• Poor signal detection:

  • Challenge: Weak or absent signal in Western blot despite proper sample preparation

  • Solutions:

    • Increase antibody concentration (try 1:500 instead of 1:2000)

    • Extend primary antibody incubation time (overnight at 4°C)

    • Use signal enhancement systems (e.g., biotin-streptavidin amplification)

    • Ensure adequate protein loading (40-60 μg for cell lysates)

    • Use positive control samples (LO2, A-549, or A-431 cells)

• High background or non-specific binding:

  • Challenge: Multiple bands or high background obscuring specific TATDN1 signal

  • Solutions:

    • Increase blocking time and concentration (5% BSA or milk for 2 hours)

    • Add 0.1-0.3% Tween-20 to washing buffer

    • Reduce primary antibody concentration

    • Pre-absorb antibody with cell lysate from TATDN1-knockdown cells

    • Use freshly prepared buffers and reagents

• Inconsistent results across experiments:

  • Challenge: Variable detection of TATDN1 in the same samples across different experiments

  • Solutions:

    • Standardize protein extraction protocol (particularly important for nuclear proteins)

    • Aliquot antibodies to avoid freeze-thaw cycles

    • Document lot numbers and prepare standardized protocols

    • Include internal loading controls in every experiment

    • Maintain consistent experimental conditions (temperature, incubation times)

• Discrepancies between detection methods:

  • Challenge: TATDN1 detected by Western blot but not by immunofluorescence (or vice versa)

  • Solutions:

    • Verify antibody validation for each specific application

    • Optimize fixation methods for immunofluorescence (try both paraformaldehyde and methanol)

    • Consider epitope masking issues in different applications

    • Use multiple antibodies targeting different epitopes

• Detection in cancer samples:

  • Challenge: Variable detection in heterogeneous tumor samples

  • Solutions:

    • Use laser capture microdissection to isolate specific cell populations

    • Compare with matched normal tissue controls

    • Consider tumor microenvironment effects on protein expression

    • Analyze correlation with other markers like β-catenin and Ezrin

By implementing these technical solutions, researchers can improve the reliability and reproducibility of their TATDN1 antibody-based experiments .

How can TATDN1 antibodies be used to investigate therapeutic targeting in cancer?

TATDN1 antibodies can serve as valuable tools for investigating therapeutic targeting strategies in cancer, particularly in drug-resistant tumors:

• Target validation in preclinical models:

  • Use TATDN1 antibodies to confirm protein expression in patient-derived xenografts and cell lines

  • Correlate TATDN1 levels with treatment response in drug-resistant models

  • Monitor changes in TATDN1 expression during acquired resistance development

  • The established role of TATDN1 in cisplatin resistance makes it particularly relevant for NSCLC therapeutic development

• Mechanistic pathway investigation:

  • Employ TATDN1 antibodies in co-immunoprecipitation studies to identify interacting partners

  • Use chromatin immunoprecipitation (ChIP) to examine DNA-binding properties related to its DNase activity

  • Investigate post-translational modifications that might affect TATDN1 function

  • Map the complete TATDN1-mediated signaling network, expanding beyond known interactions with β-catenin and Ezrin

• Therapeutic response monitoring:

  • Develop immunohistochemistry protocols using TATDN1 antibodies as potential biomarkers

  • Track changes in TATDN1 expression during treatment to predict drug resistance

  • Correlate TATDN1 levels with patient outcomes in clinical trials

  • Investigate whether TATDN1 levels could serve as a companion diagnostic for targeted therapies

• Novel therapeutic approach development:

  • Use antibodies to validate knockdown efficiency in RNA interference approaches

  • Monitor protein depletion in proteolysis-targeting chimera (PROTAC) development

  • Evaluate the efficacy of small molecule inhibitors targeting TATDN1 or its downstream effectors

  • Explore combination therapies targeting both TATDN1 and its regulatory network components

By leveraging TATDN1 antibodies in these research contexts, investigators can accelerate the development of targeted therapies for cancers where TATDN1 plays a significant role in disease progression or treatment resistance .

What future research directions might expand our understanding of TATDN1 function?

Several promising research directions could significantly expand our understanding of TATDN1's biological functions and therapeutic potential:

• Structural biology approaches:

  • Determine the three-dimensional structure of TATDN1 protein to better understand its DNase mechanism

  • Map critical functional domains and catalytic sites

  • Identify structural changes associated with post-translational modifications

  • Design structure-based inhibitors targeting specific functional domains

• Systems biology integration:

  • Develop comprehensive protein-protein interaction networks centered on TATDN1

  • Perform multi-omics analysis (proteomics, transcriptomics, metabolomics) in TATDN1-manipulated systems

  • Investigate how TATDN1 integrates into broader cellular pathways beyond the currently known interactions with E-cadherin, HER2, β-catenin, and Ezrin

  • Explore potential feedback mechanisms regulating TATDN1 expression and function

• Expanded disease relevance:

  • Investigate TATDN1's role in cancers beyond NSCLC

  • Explore potential functions in non-cancer diseases, particularly those involving DNA damage repair

  • Examine TATDN1's role in normal development, expanding on its known involvement in eye development

  • Study potential immune system interactions, given its nuclear location and DNase activity

• Advanced technological applications:

  • Develop CRISPR-engineered cell lines with tagged endogenous TATDN1 for live-cell imaging

  • Create conditional knockout models to study tissue-specific functions

  • Apply single-cell analysis to understand heterogeneity in TATDN1 expression within tumors

  • Utilize cryo-electron microscopy to visualize TATDN1 interactions with DNA substrates

• Therapeutic development pipeline:

  • Expand on the TATDN1/miR-451/TRIM66 regulatory axis as a therapeutic target

  • Investigate small molecule approaches to disrupt TATDN1's interaction with downstream effectors

  • Develop antisense oligonucleotides targeting TATDN1 lncRNA function

  • Explore nanotechnology-based delivery systems for TATDN1-targeting therapeutics

These research directions represent promising avenues that could significantly advance our understanding of TATDN1 biology and potentially lead to novel therapeutic strategies for TATDN1-associated diseases .